Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genmab A/S

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

30 comunicati stampa

Guarda tutti i comunicati
13/04/2026
Industria
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
16/01/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
07/01/2026
Scienza
Sanità
Farmaceutica
Oncologia
Tecnica
Medicina - Varie
Biotecnologia
Tecnologie Varie
Salute
Mercato del lavoro
Industria
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
29/12/2026
Biotecnologia
Sanità
Salute
Medicina - Varie
Genmab Portfolio Prioritization Update
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
12/12/2025
Mercato azionario
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
08/12/2025
Eventi
Fiere
Industria
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
07/12/2025
Industria
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
06/12/2025
Eventi
Industria
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
18/11/2025
Igiene alimentare
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Industria
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
03/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Industria
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0